SCHEMBL2950386

SCHEMBL2950386

CCN(CC)S(=O)(=O)c1sc2ccc(-c3ccc(C(=O)OC)cc3)cc2c1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CMA1 P23946 8/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ TSHR P16473 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ PFKFB3 Q16875 5/20 0.45
▸ PFKFB4 Q16877 5/20 0.45
▸ GAA P10253 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ KDM4E B2RXH2 3/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ MAPT P10636 2/20 0.39
▸ HPGD P15428 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2950845 0.88 SMN1; SMN2 (0.43) CMA1SMN1; SMN2TSHRPFKFB3PFKFB4
SCHEMBL2950077 0.80 CMA1 (0.56) CMA1PFKFB3PFKFB4CA12CA1
SCHEMBL2950050 0.74 CMA1 (0.46) CMA1PFKFB3PFKFB4GAAL3MBTL1
SCHEMBL2953473 0.74 NPSR1 (0.54) CMA1PFKFB3PFKFB4L3MBTL1
SCHEMBL2951665 0.73 ERN1 (0.51) CMA1PFKFB3PFKFB4GAAL3MBTL1
SCHEMBL2952553 0.73 CMA1 (0.48) CMA1PFKFB3PFKFB4
SCHEMBL2945363 0.72 CMA1 (0.44) CMA1PFKFB3PFKFB4GAAL3MBTL1
SCHEMBL2948556 0.72 CMA1 (0.44) CMA1PFKFB3PFKFB4GAAL3MBTL1
SCHEMBL2949116 0.67 PIK3CA (0.46) CMA1SMN1; SMN2TSHRCYP1A2CYP2C19
SCHEMBL2943649 0.67 ERN1 (0.46) GAAALDH1A1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 — — US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 — — US disclosed
US-7504512-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-03-17 — — US disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 — — EP disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 — — US disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 — — EP disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 — — US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 — — US disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 CMA1 2808/4885SMN1; SMN2 1440/4885TSHR 4377/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 CMA1 3144/4885SMN1; SMN2 1656/4885TSHR 4350/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR CMA1 4006/4885SMN1; SMN2 1713/4885TSHR 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback